Squarepoint
BCAX

Squarepoint’s Bicara Therapeutics BCAX Stock Holding History

Squarepoint’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,771
Closed -$214K – 5094
2026
Q1 		$214K Buy
+10,771
New +$185K ﹤0.01% 3924
2025
Q3 		– Sell
-13,363
Closed -$124K – 5127
2025
Q2 		$124K Buy
+13,363
New +$159K ﹤0.01% 4112
2024
Q4 		– Sell
-44,774
Closed -$1.14M – 5586
2024
Q3 		$1.14M Buy
+44,774
New +$1.14M ﹤0.01% 2501

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Squarepoint's BCAX Position: Q2 2026 in Review

Squarepoint sold out of Bicara Therapeutics (BCAX) in Q2 2026, closing a stake of 10,771 shares — an estimated $214K sold.

Squarepoint first reported a position in BCAX in Q3 2024 and held it in 3 quarters. The position peaked at $1.14M in Q3 2024. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Squarepoint reported no remaining Bicara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 10,771 Bicara Therapeutics shares in Q2 2026, an estimated $214K.
  • Squarepoint first reported a position in Bicara Therapeutics in Q3 2024 and held it in 3 quarters.
  • Squarepoint's Bicara Therapeutics position peaked at $1.14M in Q3 2024.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.